Ad
related to: jakafi 10mg cost list for sale by ownergoodrx.com has been visited by 100K+ users in the past month
Ranked at No. 20 on the 2020 Disruptor 50 list. - CNBC
- Free Discount Card
Get a Free Discount Card Today and
Start Saving up to 80% Off Your Rx
- GoodRx® Press
"Shop wisely with GoodRx"
Featured on CNN & Forbes.
- GoodRx® Blog
Get the Latest Healthcare News
Find What Matters Most to You
- GoodRx® & Medicare
Beat your Medicare Copay!
Discover More Savings Options Today
- Free Discount Card
Search results
Results from the WOW.Com Content Network
Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...
The prescribing information for Jakafi now includes a new recommended starting dose of 5 mg twice daily of Jakafi for patients with baseline platelet counts between 50-100 x 10 9 /L (50,000 to ...
In this study, where twice as many patients were randomized to Jakafi (146) as to placebo (73), there were 14 percent (n=20) deaths in the group treated with Jakafi and 22 percent (n=16) in the ...
For premium support please call: 800-290-4726 more ways to reach us
In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. [24] [25] Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of ...
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).
New Data for Jakafi® (ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting Incyte to host a webcast for investors featuring highlights from multiple ...
A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.